中国肺癌杂志2016，Vol.19Issue(4)：200-206,7.DOI:10.3779/j.issn.1009-3419.2016.04.04
埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析
Clinical Analysis of Icotinib on Beneifciary of Advanced Non-small Cell Lung Cancer with EGFR Common Mutation
蒋小雯 1王文娴 1张沂平1
作者信息
- 1. 310000 杭州，浙江中医药大学附属浙江省肿瘤医院胸部肿瘤内科
- 折叠
摘要
Abstract
Background and objective Targeted therapy has become an indispensable therapy method in advanced non-small cell lung cancer (NSCLC) treatment. Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can signiifcantly prolong the survival of patients harboring EGFR gene mutation. Icotinb is China's ifrst EGFR-TKI with indepen-dent intellectual property rights. hTe aim of this study is to investigate the clinical characteristics about the beneifciary of ad-vanced NSCLC patients with EGFR Common mutation who were treated with Icotinib. Retrospectively collect the data about beneifciary [progression-free survival (PFS)≥6 months] and analysis of the related risk factors for prognosis. Methods From September 1, 2011 to September 30, 2015, 231 cases of advanced NSCLC beneifciary with EGFR common mutation were enrolled for treatment with icotinib in Zhejiang Cancer Hospital. Results hTe one year beneift rate was 67.9%in the group treated with Icotinib as ifrst line, and in the groupas second line or above was 53.6%, which is statisticallysigniifcant. hTe two years beneift rate was 18.7%and 9.3%, respectively. hTe median PFS of ifrst line group and the second line or above was 16.7 and 12.4 months, respectively. hTe presence of brain metastasis (P=0.010), Prior chemotherapy (P=0.001), Eastern Coopera-tive Oncology Group (ECOG) score (P=0.001) were the main factors inlfuencing the prognosis. hTe most common adverse were skin rashes (51 cases, 22.1%) and diarrhea (27 cases, 11.7%). Conclusion Icotinib offers long-term clinical beneift and good tolerance for advanced NSCLC harboring EGFR gene mutation. Its advantage groups in addition to the patients with brain metastases and better ECOG score, the curative effect of patients with the ifrst-line treatment is superior to second or fur-ther line.关键词
肺肿瘤/EGFR突变/埃克替尼/获益者Key words
Lung neoplasms/EGFR mutation/Icotinib/Beneifciary引用本文复制引用
蒋小雯,王文娴,张沂平..埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析[J].中国肺癌杂志,2016,19(4):200-206,7.
